Prognostic factors and adjuvant therapy in uterine carcinosarcoma

Purpose of investigation: The objective of this retrospective study was to investigate prognostic variables and impact of adjuvant therapy in uterine carcinosarcoma. Methods: The clinical information and pathological confirmation were reviewed for cases with uterine carcinosarcoma from 1984 to 2005. A total of 45 patients were eligible for analysis. Results: The median follow-up for survivors was 84 months. Five-year overall survival and progression-free survival (PFS) rates were 36.5% and 33.8%, respectively for Stage I-IV. Distant site metastasis with/without pelvic failure occurred in 83.3% of those with recurrence/progression. By multivariate analysis, older age (p = 0.001) and more than half of myometrial invasion (p = 0.002) were significant predictors of death, while only myometrial invasion (p = 0.022) was significantly associated with PFS. Stratified analyses demonstrated a monotonic trend of chemotherapy or chemoradiation to decrease death. Conclusions: Our results suggested that age and depth of myometrial invasion were significant prognostic factors, and chemotherapy or chemoradiation seemed to be beneficial for uterine carcinosarcoma.

Uterine carcinosarcoma; Chemotherapy, Chemoradiation , Malignant mixed müllerian tumor, Prognostic factor

[1] Brooks S.E., Zhan M., Cote T., Baquet C.R.: “Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989-1999”. Gynecol. Oncol., 2004, 93, 204.

[2] Nordal R.R., Thoresen S.Ø.: “Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality”. Eur. J. Cancer, 1996, 33, 907.

[3] McCluggage W.G..: “Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?”. J. Clin. Pathol., 2002, 55, 321.

[4] Silverberg S.G., Major F.J., Blessing J.A., Fetter B., Askin F.B., Liao S.Y. et al.: “Carcinosarcoma (MMMT) of the uterus: a GOG pathologic study of 203 cases”. Int. J. Gynecol. Pathol., 1990, 9, 1.

[5] Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman W.T., Currie J.L. et al.: “Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study”. Cancer, 1993, 71 (suppl.), 1702.

[6] Iwasa Y., Haga H., Konishi I., Kobashi Y., Higuchi K., Katsuyama E. et al.: “Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients”. Cancer, 1998, 82, 512.

[7] Yamada D.S., Burger R.A., Brewster W.R., Anton D., Kohler M.F., Monk B.J.: “Prognostic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus”. Cancer, 2000, 88, 2782.

[8] Sartori E., Bazzurini L., Gadducci A., Landoni F., Lissoni A., Maggino T. et al.: “Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study”. Gynecol. Oncol., 1997, 67, 70.

[9] Amant F., Cadron I., Fuso L., Berteloot P., Jonge E., Jacomen G. et al.: “Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk endothelial endometrial cancer”. Gynecol. Oncol., 2005, 98, 274.

[10] Kanjeekal S., Chambers A., Fung M.F.K., Verma S.: “Systemic therapy for advanced uterine sarcoma: a systematic review of the literature”. Gynecol. Oncol., 2005, 97, 624.

[11] McCluggage W.G., Haller U., Kurman R.J.: “Mixed epithelial and mesenchymal tumours”. In: Tavassoli F.A., Decilee P. (eds.).World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, 2003, 245.

[12] SPSS for windows, Rel 11.0.1. Chicago, SPSS. Inc., 2001.

[13] SAS Statistical Package, Version 8.1. Cary, NC: SAS Institute, Inc., 2000.

[14] Gerszten K., Faul C., Kounelis S., Huang Q., Kelly J., Jones M.W.: “The impact of adjuvant radiotherapy on carcinosarcoma of the uterus”. Gynecol. Oncol., 1998, 68, 8.

[15] Callister M., Ramondetta L.M., Jhingran A., Burke T.W., Eifel P.J.: “Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome”. Int. J. Radiat. Oncol. Biol. Phy., 2004, 58, 786.

[16] Manolitsas T.P.,Wain G.V.,Willians K.E., Freidlander M., Hacker N.F.: “Multimodality therapy for patients with clinical Stage I and II malignant mixed müllerian tumors of the uterus”. Cancer, 2001, 91, 1437.

[17] Menczer J., Levy T., Piura B., Chetrit A., Altaras M., Meirovitz M. et al.: “A comparison between different postoperative treatment modalities of uterine carcinosarcoma”. Gynecol. Oncol., 2005, 97, 166.

[18] Sutton G., Kauderer J., Carson L.F., Lentz S.S., Whitney C.W., Gallion H.: “Adjuvant ifosfamide and cisplatin in patients with completely resected Stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncologic Group study”. Gynecol. Oncol., 2005, 96, 630.

[19] Wolfson A.H., Brady M.F., Mannel R.S., Lee Y., Futoran R.J., Cohn D. et al.: “A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs cisplatinifosfamide+mesna (CIM) in optimally debulked Stage I-IV carcinosarcoma (CS) of the uterus”. Gynecol. Oncol., 2007, 107, 166.

[20] Omura G.A., Major F.J., Blessing J.A., Sedlacek T.V., Thigpen J.T., Creasman W.T. et al.: “A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas”. Cancer, 1983, 52, 626.

[21] Sutton G., Brunetto V.L., Kilgore L., Soper J.T., McGehee R., Olt G. et al.: “A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group study”. Gynecol. Oncol., 2000, 79, 147.

[22] Homesley H.D., Filiaci V., Markman M., Bitterman P., Eaton L., Kilgore L.C. et al.: “Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2007, 25, 526.

[23] Miller D.S., Blessing J.A., Schilder J., Munkarah A., Lee Y.C.: “Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2005, 98, 217.

[24] Carmen M.G., Fuller A.F., Matulonis U., Horick N.K., Goodman A., Duska L.R. et al.: “Phase II trial of anastrozole in women with asymptomatic müllerian cancer”. Gynecol. Oncol., 2003, 91, 596.

[25] Kuo D.Y.S., Timmins P., Blank S.V., Fields A.L., Goldberg G.L., Murgo A. et al.: “Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York phase II consortium”. Gynecol. Oncol., 2006, 100, 160.